For research use only. Not for therapeutic Use.
BMS-986260 (Cat.No:I020709) is a potent, selective, and orally bioavailable TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.
| Catalog Number | I020709 |
| CAS Number | 2001559-19-7 |
| Synonyms | BMS-986260; BMS 986260; BMS986260; |
| Molecular Formula | C18H12ClFN6O |
| Purity | ≥95% |
| Target | TGF-β Receptor |
| IUPAC Name | 6-[5-(3-chloro-4-fluorophenyl)-3-(2-hydroxyethyl)imidazol-4-yl]imidazo[1,2-b]pyridazine-3-carbonitrile |
| InChI | InChI=1S/C18H12ClFN6O/c19-13-7-11(1-2-14(13)20)17-18(25(5-6-27)10-23-17)15-3-4-16-22-9-12(8-21)26(16)24-15/h1-4,7,9-10,27H,5-6H2 |
| InChIKey | VZZBCNXVZFAIQX-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1C2=C(N(C=N2)CCO)C3=NN4C(=NC=C4C#N)C=C3)Cl)F |
